Trimetazidine and COVID-19-induced acute cardiac injury: a missed key.
作者信息
Al-Kuraishy Hayder M, Al-Gareeb Ali I, Welson Nermeen N, Batiha Gaber El-Saber
机构信息
Professor in department of clinical pharmacology and medicine, college of medicine, ALmustansiriyia University, M.B.Ch.B, FRCP, Baghdad, Iraq.
Department of forensic medicine and clinical toxicology, faculty of medicine, Beni-Suef University, Beni Suef, Egypt.
出版信息
Int J Clin Pharm. 2022 Jun;44(3):832-833. doi: 10.1007/s11096-022-01408-5. Epub 2022 Apr 21.
Abstract
摘要
相似文献
1
Trimetazidine and COVID-19-induced acute cardiac injury: a missed key.曲美他嗪与新型冠状病毒肺炎所致急性心脏损伤：一个被忽视的关键因素。
Int J Clin Pharm. 2022 Jun;44(3):832-833. doi: 10.1007/s11096-022-01408-5. Epub 2022 Apr 21.
2
[Significance of trimetazidine for out of hospital physical rehabilitation after myocardial infarction].曲美他嗪对心肌梗死后院外身体康复的意义
Kardiologiia. 2002;42(11):14-20.
3
[Trimetazidine (Preductal). A new approach in controlling myocardial ischemia].[曲美他嗪（冠脉舒）。控制心肌缺血的新方法]
Ter Arkh. 1996;68(8):57-63.
4
Effects of trimetazidine on atrial structural remodeling and platelet activation in dogs with atrial fibrillation.曲美他嗪对心房颤动犬心房结构重塑和血小板活化的影响。
Chin Med J (Engl). 2009 Sep 20;122(18):2180-3.
5
6
Trimetazidine in the myocardial cell mechanisms of cytoprotection.曲美他嗪在心肌细胞中的细胞保护机制
Rom J Intern Med. 1998 Jul-Dec;36(3-4):137-44.
7
Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention.在经皮冠状动脉介入治疗后，服用曲美他嗪可使心肌损伤降至最低，并改善左心室功能。
Am J Cardiovasc Drugs. 2007;7(2):143-50. doi: 10.2165/00129784-200707020-00006.
8
The potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy.曲美他嗪对糖尿病合并缺血性心肌病患者的潜在益处。
Am Heart J. 2004 Dec;148(6):e31; author reply e32. doi: 10.1016/j.ahj.2004.03.059.
9
10
Comments on EMIP-FR study's editorial.关于EMIP-FR研究社论的评论。
Eur Heart J. 2001 Aug;22(15):1359. doi: 10.1053/euhj.2001.2539.
引用本文的文献
1
The Potential Nexus between Helminths and SARS-CoV-2 Infection: A Literature Review.寄生虫与 SARS-CoV-2 感染之间的潜在关联：文献综述。
J Immunol Res. 2023 Jun 20;2023:5544819. doi: 10.1155/2023/5544819. eCollection 2023.
2
Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?肥胖中的脂肪细胞：新冠病毒的完美储存库？
Med Hypotheses. 2023 Feb;171:111020. doi: 10.1016/j.mehy.2023.111020. Epub 2023 Jan 27.
3
Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.在 COVID-19 中胆碱能功能障碍：疯狂寻找和期待最好的结果。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Mar;396(3):453-468. doi: 10.1007/s00210-022-02346-9. Epub 2022 Dec 3.
4
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.针对 COVID-19 的神经炎症的格列本脲靶向治疗：来自兵工厂的旧武器。
Inflammopharmacology. 2023 Feb;31(1):1-7. doi: 10.1007/s10787-022-01087-8. Epub 2022 Nov 23.
5
Pregnancy and COVID-19: high or low risk of vertical transmission.妊娠与 COVID-19：垂直传播的高或低风险。
Clin Exp Med. 2023 Aug;23(4):957-967. doi: 10.1007/s10238-022-00907-z. Epub 2022 Oct 17.
6
The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument.伊伐布雷定在多柔比星所致心脏毒性中的作用：潜在论点探讨。
Inflammopharmacology. 2022 Dec;30(6):2441-2446. doi: 10.1007/s10787-022-01082-z. Epub 2022 Oct 11.
7
Pathophysiology of Post-COVID syndromes: a new perspective.新冠后综合征的病理生理学：新视角。
Virol J. 2022 Oct 9;19(1):158. doi: 10.1186/s12985-022-01891-2.
8
Montelukast and Acute Coronary Syndrome: The Endowed Drug.孟鲁司特与急性冠状动脉综合征：捐赠药物。
Pharmaceuticals (Basel). 2022 Sep 14;15(9):1147. doi: 10.3390/ph15091147.
9
The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not?生长分化因子15在新型冠状病毒肺炎中的潜在作用：是伴随的主观效应还是并非如此？
Diagnostics (Basel). 2022 Aug 24;12(9):2051. doi: 10.3390/diagnostics12092051.
10
Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection.新型冠状病毒肺炎患者的血液粘度变化
Front Med (Lausanne). 2022 Jun 17;9:876017. doi: 10.3389/fmed.2022.876017. eCollection 2022.
本文引用的文献
1
Covid-19 and development of heart failure: mystery and truth.Covid-19 与心力衰竭的发生：扑朔迷离与真相大白。
Naunyn Schmiedebergs Arch Pharmacol. 2021 Oct;394(10):2013-2021. doi: 10.1007/s00210-021-02147-6. Epub 2021 Sep 4.
2
Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication.VPS34 和脂肪酸代谢抑制剂抑制 SARS-CoV-2 复制。
Cell Rep. 2021 Aug 3;36(5):109479. doi: 10.1016/j.celrep.2021.109479. Epub 2021 Jul 20.
3
Evaluation of the Efficacy and Safety of Chinese Herbal Injection Combined With Trimetazidine for Viral Myocarditis: A Network Meta-Analysis.中药注射剂联合曲美他嗪治疗病毒性心肌炎的疗效与安全性评价：一项网状Meta分析
Front Pharmacol. 2021 Apr 29;12:630896. doi: 10.3389/fphar.2021.630896. eCollection 2021.
4
Clinical Profile and 30-Day Mortality of Invasively Managed Patients with Suspected Acute Coronary Syndrome During the COVID-19 Outbreak.COVID-19 疫情期间疑似急性冠状动脉综合征行有创治疗患者的临床特征和 30 天死亡率。
Int Heart J. 2021 Mar 30;62(2):274-281. doi: 10.1536/ihj.20-574. Epub 2021 Mar 17.
5
Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects.序贯多西环素和秋水仙碱联合治疗 COVID-19：有益作用。
Pulm Pharmacol Ther. 2021 Apr;67:102008. doi: 10.1016/j.pupt.2021.102008. Epub 2021 Mar 14.
6
Trimetazidine in Heart Failure.曲美他嗪用于心力衰竭
Front Pharmacol. 2021 Jan 12;11:569132. doi: 10.3389/fphar.2020.569132. eCollection 2020.
7
Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus.从病毒角度看新型冠状病毒肺炎（COVID-19）诱发心脏损伤的发病机制
J Mol Cell Cardiol. 2020 Oct;147:12-17. doi: 10.1016/j.yjmcc.2020.08.002. Epub 2020 Aug 6.
8
Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.中国湖南普通型 2019 冠状病毒病患者的临床特征和药物治疗方法。
Int J Clin Pharm. 2020 Jun;42(3):837-845. doi: 10.1007/s11096-020-01031-2. Epub 2020 May 14.
9
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究：中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
10
Trimetazidine Attenuates Exhaustive Exercise-Induced Myocardial Injury in Rats via Regulation of the Nrf2/NF-κB Signaling Pathway.曲美他嗪通过调节Nrf2/NF-κB信号通路减轻大鼠力竭运动诱导的心肌损伤。
Front Pharmacol. 2019 Mar 5;10:175. doi: 10.3389/fphar.2019.00175. eCollection 2019.
Zotero 插件